Armata's second quarter reads two different ways at once, and both readings are the same quarter. On the GAAP income statement, net income flipped to a $74.1 million profit from a $16.3 million loss a year earlier, with diluted basic earnings of $2.02 a share; on the balance sheet, cash climbed to $24.0 million from $8.7 million; on the regulatory side, the company submitted its complete Phase 3 superiority protocol to the FDA for its lead intravenous phage therapeutic, secured Fast Track designation, and locked an Agreed Initial Pediatric Study Plan with the agency. None of those three stories is fake. They sit on the same page because the GAAP profit is a non-cash mark-to-market swing on a convertible loan - a $91.0 million gain as the stock price rose versus a $5.8 million loss a year ago - not an operating turn. The business is a single-program, late-clinical-stage antibiotic-resistance biotech that is preparing to start its pivotal trial. The single most important fact about this quarter is the company's own 12-month going-concern paragraph in the same 10-Q. Cash on hand, plus another $25 million term loan funded in May 2026, will not carry operations to FDA submission on its own. The pivot to a pivotal Phase 3 is happening now, and so is the cash call that follows.
The stock closed at $4.82 on August 13, 2026, the day after the print, giving the company a market capitalization of roughly $179 million against a $231 million stockholders' deficit, $164 million of convertible debt carried at fair value, and roughly $120 million of face-value term debt - almost all of it from Innoviva Strategic Opportunities, the principal stockholder, which is the company's controlling shareholder. The market is paying a little under 10x trailing grant revenue (a government-funded development contract that is not a commercial product line) and roughly 1.5x the post-deal unrestricted cash. The valuation is not anchored on a near-term product; it is anchored on whether Armata can start, run, and read out a 450-patient Phase 3 superiority study in complicated *S. aureus* bacteremia before its cash, its lender's patience, or its public-equity tolerance for dilution runs out. The thesis is a clinical readout, not a financial story; the load-bearing observation is the company has just spent a quarter that checked every operational box on the way to a pivotal study, and it has done so with a balance sheet whose own auditor flagged a going-concern question. The next two reporting cycles are the test.